Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rapamycin Therapy for Patients With Activated Phosphoinositide 3-Kinase δ Syndrome

NCT03383380 is registered in ClinicalTrials.gov with Children's Hospital of Fudan University as lead sponsor.

NCT NCT03383380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03383380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rapamycin Therapy for Patients With Activated Phosphoinositide 3-Kinase δ Syndrome
Lead sponsor
Children's Hospital of Fudan University
Phase
Phase 1/2
Overall status
Completed
Start date
December 1, 2017
Completion date
November 30, 2023
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

activated pi3k-delta syndrome, immunodeficiency primary